PML-RARA–targeted DNA vaccine induces protective immunity in a mouse model of leukemia
- 19 October 2003
- journal article
- letter
- Published by Springer Nature in Nature Medicine
- Vol. 9 (11) , 1413-1417
Abstract
Despite improved molecular characterization of malignancies and development of targeted therapies, acute leukemia is not curable and few patients survive more than 10 years after diagnosis. Recently, combinations of different therapeutic strategies (based on mechanisms of apoptosis, differentiation and cytotoxicity) have significantly increased survival. To further improve outcome, we studied the potential efficacy of boosting the patient's immune response using specific immunotherapy. In an animal model of acute promyelocytic leukemia, we developed a DNA-based vaccine by fusing the human promyelocytic leukemia–retinoic acid receptor-α (PML-RARA) oncogene to tetanus fragment C (FrC) sequences. We show for the first time that a DNA vaccine specifically targeted to an oncoprotein can have a pronounced effect on survival, both alone and when combined with all-trans retinoic acid (ATRA). The survival advantage is concomitant with time-dependent antibody production and an increase in interferon-γ (IFN-γ). We also show that ATRA therapy on its own triggers an immune response in this model. When DNA vaccination and conventional ATRA therapy are combined, they induce protective immune responses against leukemia progression in mice and may provide a new approach to improve clinical outcome in human leukemia.Keywords
This publication has 26 references indexed in Scilit:
- CpG motifs: the active ingredient in bacterial extracts?Nature Medicine, 2003
- Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humansNature Medicine, 2003
- Prophylactic cancer vaccinesCurrent Opinion in Immunology, 2002
- Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytomaEuropean Journal of Immunology, 1996
- Idiotypic DNA Vaccines Against B‐cell LymphomaImmunological Reviews, 1995
- An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues.Journal of Experimental Medicine, 1993
- The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RARCell, 1991
- Direct Gene Transfer into Mouse Muscle in VivoScience, 1990
- Heterogeneity of natural killer cells in the mouse.Journal of Experimental Medicine, 1981
- Adjuvanticity of Vitamin ANature, 1968